Meet Hal Leshner, first-time hiker in the CF Foundation's Xtreme Hike, a fundraising event that challenges members of the CF community, and their families and friends, to take on the great outdoors.
Site Search
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Meet a few faces from the 2015 Pittsburgh's 50 Finest event and learn how they raised funds and awareness for the CF cause.
This year our CF Foundation employee Great Strides team adopted a “Star Wars” theme and, believe me, we went all out to make the experience extra special and out of this world. See for yourself!
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
On April 7, the Foundation presented the Alex, Jena, and Dream Big Awards to leaders in the cystic fibrosis community for their dedication to the Foundation's mission of finding a cure.
The Cystic Fibrosis Foundation announced the recipients of its fifth annual Impact Grants.
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.